Introduction
•Definition
: Disturbance of consciousness and a change in cognition that develop over a short time.
•It
is a syndrome, not a disease.
•Has
many causes.
•Classically,
delirium has a sudden
onset (hours or days), a brief fluctuating
course, and a rapid improvement when the causative
factors is identified and eliminated.
Epidemiology
•Prevalence
– 0.4% age >18, 1.1% age >55
•10-30%
of medically ill patients who are hospitalized.
•30%
of patients in surgical and cardiac ICU.
•30-40%
of patients with acquired immune deficiency syndrome who are hospitalize.
•80%
of terminally ill patients.
•Advanced
age (30-40% hospitalize
patients age > 65 years old)
•Nursing
home residents (60% age >75 years old)
•Other
predisposing factors - preexisting brain damage (eg: cerebrovascular disease, tumor),
history of delirium, alcohol dependence, diabetes, cancer and malnutrition.
•Male
Etiology
Major causes:
•central
nervous system disease (eg: epilepsy)
•systemic
disease (eg: cardiac failure)
•Intoxication/withdrawal
from pharmacological or toxic agents
*clinicians should assume that any drug that a patient
has taken may be the cause of delirium
Clinical Features
Diagnosis
1.Delirium due to a general medical condition
2.Substance intoxication delirium
3.Substance withdrawal delirium
4.Delirium due to multiple etiologies
5.Delirium not otherwise specified
Course and Prognosis
•Symptoms usually
persist as long as the causally relevant factors are present
•Generally, delirium
lasts less than a week
•Symptoms usually
recede over a 3 to 7 day period, after removal of causative factors
•Some symptoms may
take up to 2 weeks to resolve
•The occurrence of
delirium is associated with a high mortality rate in the ensuing year
•Periods of delirium
are sometimes followed by depression or PTSD
Treatment
•Primary goal: treat
underlying cause
•Physical support to
prevent accidents
•Pharmacotherapy
i.Psychosis
•Haloperidol
2 to 6 mg IM
•2nd
generation anti-psychotics
ii.Insomnia
•BDZ
with short/intermediate half-lives (e.g lorazepam 1 to 2 mg at
bedtime)
BDZ with long
half-lives should be avoided unless as part of treatment for underlying
disorder
Tiada ulasan:
Catat Ulasan